Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis.

Mahdi Barzegar Shakiba Houshi Erfan Sadeghi Mozhgan Sadat Hashemi Ghasem Pishgahi Sara Bagherieh Alireza Afshari-Safavi Omid Mirmosayyeb Vahid Shayegannejad Aram Zabeti

Published in: Multiple sclerosis international (2022)

Our study showed an increased risk of severe COVID-19 in patients on rituximab and ocrelizumab. No association with COVID-19 severity across other DMTs was observed.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
respiratory syndrome coronavirus
prognostic factors
peritoneal dialysis
early onset
hodgkin lymphoma
chronic lymphocytic leukemia